The invention relates to a method for detecting epileptic or psychogenic seizures, comprising the steps of: a. recording a large number of temporally sequential parameter values for a parameter type, wherein a parameter value is determined on the basis of a series of temporally sequential RR intervals, the series of temporally sequential parameter values preferably differing in that the series that served as the basis for determining the following parameter value includes, in place of the oldest RR interval of the series that served as the basis for determining the preceding parameter value (preceding series), the RR interval temporally subsequent to the most recent RR interval of the preceding series, b. comparing the time course of the parameter values with the time course of parameter values for the same parameter type that had been determined according to method step a, and the determination thereof is based on RR intervals that indicate a seizure (parameter reference values), c. identifying a seizure when the time course of the parameter values exhibits a characteristic of the time course of the parameter reference values (course characteristic) indicating a seizure.

Methods, systems, and apparatus for assessing a state of an epilepsy disease or a comorbidity thereof are provided. The methods comprise receiving at least one autonomic index, neurologic index, stress marker index, psychiatric index, endocrine index, adverse effect of therapy index, physical fitness index, or quality of life index of a patient; comparing the at least one index to at least one reference value; and assessing a state of an epilepsy disease or a body system of the patient based on the comparison. A computer readable program storage device encoded with instructions that, when executed by a computer, perform the method described above is also provided. A medical device system capable of implementing the method described above is also provided.

Methods, devices and systems are described for evaluating an initial orthostatic response of an individual during an orthostatic test. For example, the method may include: receiving a pulse signal obtained during an orthostatic test performed from a sensor placed on the individual; identifying a position and an amplitude of the dicrotic notch for pulses in a portion of the pulse signal to obtain a set of dicrotic notch positions and amplitudes; generating an initial orthostatic response curve from the set of dicrotic notch positions and amplitudes; evaluating the initial orthostatic response curve to obtain an assessment of the initial orthostatic response; and displaying, storing and/or transmitting at least one of the initial orthostatic response curve and a visual representation of the assessment of the initial orthostatic response curve.

An intravascular catheter for nerve activity ablation and/or sensing includes one or more needles advanced through supported guide tubes (needle guiding elements) which expand to contact the interior surface of the wall of the renal artery or other vessel of a human body allowing the needles to be advanced though the vessel wall into the extra-luminal tissue including the media, adventitia and periadvential space. The catheter also includes structures which provide radial and lateral support to the guide tubes so that the guide tubes open uniformly and maintain their position against the interior surface of the vessel wall as the sharpened needles are advanced to penetrate into the vessel wall. Electrodes near the distal ends of the needles allow sensing of nerve activity before and after attempted renal denervation. In a combination embodiment ablative energy or fluid is delivered from the needles in or near the adventitia to ablate nerves outside of the media while sparing nerves within the media.

The present invention relates to an antidepressant composition containing king oyster mushroom extract as an active ingredient, and more specifically, to a food composition and a pharmaceutical composition containing an extract or fraction of king oyster mushroom as an active ingredient for preventing, improving or treating depression. The king oyster mushroom extract of the present invention can act on serotonin receptors and inhibit the binding between serotonin receptors and selective serotonin reuptake inhibitors and act on serotonin receptors to activate serotonin receptor-mediated signaling. Also, as the king oyster mushroom extract can reduce immobility time in animal model experiments of forced swimming tests, the effect of being useful as functional foods and medicines to prevent, improve, or treat depression can be provided.

An example of a system for delivering neurostimulation to a patient and controlling the delivery of neurostimulation using sensors may include a stimulation output circuit, a sensing circuit, and a control circuit. The stimulation output circuit may be configured to deliver the neurostimulation. The sensing circuit may be configured to receive sensed signals from the sensors and to process the sensed signals. The sensing circuit has adjustable settings controlling the processing of the sensed signals. The control circuit may be configured to control the delivery of the neurostimulation using the processed sensed signals and to control the settings of the sensing circuit according to a sequence of sensing blocks each including a set of sensing parameters.

An intravascular catheter for peri-vascular nerve activity sensing or measurement includes multiple needles advanced through supported guide tubes (needle guiding elements) which expand with open ends around a central axis to contact the interior surface of the wall of the renal artery or other vessel of a human body allowing the needles to be advanced though the vessel wall into the perivascular space. The system also may include means to limit and/or adjust the depth of penetration of the needles. The catheter also includes structures which provide radial and lateral support to the guide tubes so that the guide tubes open uniformly and maintain their position against the interior surface of the vessel wall as the sharpened needles are advanced to penetrate into the vessel wall. The addition of an injection lumen at the proximal end of the catheter and openings in the needles adds the functionality of ablative fluid injection into the perivascular space for an integrated nerve sending and ablation capability.

Systems, devices, methods, and kits for monitoring one or more physiologic and/or physical signals from a subject are disclosed. A system including a head mounted display to monitor one or more physiologic signals from the face or head of the subject is disclosed. A method for analyzing an ocular parameter of the subject to determine a sympathetic and a parasympathetic outflow thereto is disclosed.

Systems, methods and devices are provided for delivering a combination of electrical impulses (and/or fields) and various stimuli to bodily tissues for various purposes. The combined therapy increases the brain's capacity to clear metabolic and neurotoxic material (waste removal), facilitates neuroplasticity to affect brain network optimization (learning and memory consolidation), and restores brain energy and neurotransmitter levels (neurometabolic restoration). In certain aspects, the systems and methods are particularly useful for enhancing sleep quantity, quality, and/or efficiency to promote more effective sleep, including more efficient waste clearance, memory consolidation, neurotransmitter rebalancing, and maintenance of energy homeostasis, leading to enhanced neurological health and reduced required sleep duration. The systems and methods may also be useful for improving a cognitive performance of the user by maintaining cognitive function during sleep deprivation and/or temporarily or permanently improving intelligence, learning capacity, memory retention, recall, mood and/or alertness.

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. A method can include transluminally delivering a distal portion of an elongated shaft of a catheter to a target renal blood vessel and at least partially inhibiting sympathetic neural activity of a renal nerve. The method includes determining a post-neuromodulation level of one or more biomarkers after at least partially inhibiting the sympathetic neural activity of the renal nerve, wherein the level of the one or more biomarkers directly or indirectly correlates with sympathetic nervous activity in the patient. The method can include comparing the post-neuromodulation level to a predetermined level for the one or more biomarkers, wherein the renal neuromodulation procedure is classified as at least partially successful if the post-neuromodulation level differs from the predetermined level.